Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-04-10

FDA Approved: COMBIVIR — Supplemental Application (ViiV Healthcare Company)

View source ↗

Summary

FDA approved a supplemental application for Combivir (lamivudine and zidovudine) submitted by ViiV Healthcare Company.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • COMBIVIR (Lamivudine and Zidovudine)

Snippet

SUPPL AP for COMBIVIR (LAMIVUDINE AND ZIDOVUDINE)